A. Gazzah

Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: Insights of the MATCH-R study

D. Planchard, S. Michiels, F. André, 2019, Annals of Oncology.

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report

D. Planchard, A. Azarine, V. Thomas de Montpréville, 2022, JTO clinical and research reports.

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report

D. Planchard, A. Azarine, V. Thomas de Montpréville, 2022, JTO clinical and research reports.

ANTIBODY DRUG CONJUGATES IN OLDER PATIENTS: STATE OF THE ART.

S. Champiat, C. Smolenschi, S. Ponce Aix, 2023, Critical reviews in oncology/hematology.

Journal Pre-proof Unexpected cardiotoxicity in HER2 -mutant non-small cell lung cancer patients treated with trastuzumab deruxtecan

D. Planchard, A. Azarine, C. Naltet, 2022 .